A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus
Completed · Phase 2
Conditions studied: Discoid Lupus Erythematosus
In brief
The purpose of this double-masked, pilot trial is to determine whether 20 percent thalidomide ointment is safe and effective for the treatment of chronic discoid lupus erythematosus (CDLE) when used under an occlusive dressing. Seventeen patients with two similar lesions will have lesions randomized to receive either intervention or placebo therapy.
Key facts
- Study ID
- NCT00001680
- Run by
- National Cancer Institute (NCI)
- People needed
- 17
- Starts
- 1997-10-01
- Expected to finish
- 2001-07-01
- Last updated by the study team
- 2008-03-04
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- National Cancer Institute (NCI) — Bethesda, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.